The biomedical industry has always been a strategic emerging industry
in Shanghai.
It is reported that at present, Shanghai has issued a total of 794 biomedical industry related policies
.
In 2022, as of late September, a total of 69 relevant policies were announced
in Shanghai.
For example, on January 20, 2022, the "14th Five-Year Plan for the Development of Shanghai's Biomedical Industry" was released, clarifying that Shanghai will aim at the development direction of "high-end, intelligent and internationalization" of the biomedical industry, deeply implement the "Zhangjiang R&D + Made in Shanghai" action, and accelerate the creation of a biomedical industry innovation highland and a world-class biomedical industry cluster
with global influence.
The "Shanghai Industrial Map (2022)" issued in July this year further optimized the layout
of the "3+6" new industrial system.
Among them, the biomedical field has focused on launching 7 characteristic industrial parks, including Life Blue Bay, Oriental Beauty Valley and Bay Area Biomedical Port, which can provide 12,000 mu
of industrial land.
In particular, Life Blue Bay has gathered 40% of the city's biomedical projects
in the past two years.
Driven by a series of favorable policies, Shanghai's biomedical innovation ability has been further enhanced, the industrial ecology has been continuously optimized, leading and backbone enterprises have grown and expanded, and a biomedical industry system
with rich innovation factors and a high degree of internationalization has gradually formed.
According to statistics, up to now, Shanghai has approved 4 new Class 1 domestic innovative drugs this year, mainly including Yingli Pharmaceutical's new anti-cancer drug Linplixet, Henlius' (new anti-cancer drug) serplulimab injection, Lepu Bio's (anti-cancer new drug) putelimab injection, and Hua Medicine's new mechanism (diabetes treatment) original innovative drug Docgliatin tablets
.
In terms of signing contracts for major project construction, Shanghai has also made new progress
since the beginning of this year.
It is reported that since the beginning of this year, Shanghai has started 32 new major projects with an investment of nearly 8 billion yuan, including the second phase of Bibo Bio's large-scale CDMO integrated platform, the construction project of Berger Medical Industrial Base, the intuitive Fosun headquarters and industrialization base, and the R&D capability and production quality improvement and transformation project of Hehuang Pharmaceutical
.
In the future, it is expected to form an industrial scale of more than 20 billion yuan, injecting strong impetus
into accelerating the development of the biomedical industry.
This year, 42 new key biomedical projects were signed, with an investment of 36.
8 billion yuan.
Recently, a number of major projects have been signed, such as Blank Bio's investment of 2 billion yuan in Minhang, and Lotus Life Science invested in the construction of a 300,000-liter CDMO production base
in Baoshan.
In terms of industrial scale, Shanghai has achieved new growth
.
Data show that in the first three quarters of this year, the scale of Shanghai's biomedical industry increased by 4.
6% year-on-year, reaching 616.
6 billion yuan; The output value of the manufacturing industry increased by 5.
5% year-on-year to 134.
545 billion yuan
.
In addition, since the beginning of this year, 11 enterprises in the field of biomedicine in Shanghai have landed on the Science and Technology Innovation Board, involving innovative drug research and development, CXO, in vitro diagnostics, medical imaging and other fields
.
In recent years, Shanghai's biomedical innovation ability has been continuously enhanced, enterprises have continued to grow, and the scale of biomedical industry has also continued to grow, fully demonstrating the strong resilience and vitality
of Shanghai's pharmaceutical industry.
It is reported that in the future, the Shanghai Municipal Science and Technology Commission will also strengthen the innovation source function from five aspects: promoting the capacity building of scientific and technological innovation sources, clinical research and transformation capacity building, innovation platform and carrier construction, innovation talent team construction, innovation atmosphere and environment construction, so as to provide inexhaustible impetus
for the high-quality development of Shanghai's biomedical industry.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
